OMDA Q3 2026: Revenue +34%, Membership +36% — Growth Decelerates Below Bull-Case Threshold

What happened

Omada Health reported third-quarter 2026 revenue of $91 million, up 34% year over year, while total membership reached 1.13 million, up 36% year over year, according to a Motley Fool article. The revenue growth exceeded the base-case assumption of >25% growth but the membership growth fell short of the >40% threshold that underpinned the bull scenario in our prior master report. The deceleration from prior-year member growth rates of 53-55% signals that the rapid scaling phase may be moderating, increasing reliance on GLP-1 program adoption and operating leverage to sustain valuation. These results arrive after the March 2026 audited print and the first-half 2026 GLP-1 launch window, so investors should look for evidence that the new prescribing business is contributing to revenue per member rather than just adding complexity. Persistent material weaknesses in internal controls and heavy dependence on Cigna affiliate payments remain key risks that could amplify any growth slowdown.

Implication

The 36% member growth in Q3 2026 is a notable step down from the >50% pace seen in late 2025 and falls below the >40% assumption embedded in the bull case, reducing the probability of that scenario. Revenue growth of 34% still comfortably exceeds the >25% base-case expectation, indicating that pricing or mix improvements may be offsetting slower member additions. Investors should closely monitor whether the GLP-1 prescribing initiative launched in 1H26 is actually lifting ARPU, as management has not yet disclosed specific adoption metrics; without that lift, the growth engine will depend entirely on volume, which is decelerating. The company's valuation at the time of the master report was ~2.9x FY2025 revenue, but if growth continues to slow toward the low 30s or below, a multiple re-rating downward is likely unless gross margin and opex leverage improve materially. Key watch items for the next two quarters include Cigna affiliate payment trends, related-party receivables, and any progress on remediating the material weaknesses, as these will determine whether the deceleration is temporary or structural.

Thesis delta

The original thesis leaned on >40% member growth to support a premium valuation; Q3 2026's 36% growth shifts the probability weight toward the base case and away from the bull case. However, revenue growth above 25% and the potential for GLP-1-driven ARPU expansion keep the core investment case intact, albeit with reduced conviction. The key question is whether management can demonstrate operating leverage and diversification to offset the slowing member engine.